Search Videos and More
News
First FDA Approval of CAR T-Cell Therapy for Multiple Myeloma Marks Milestone for Patients
The Food and Drug Administration (FDA) has granted its first approval of a CAR T-cell therapy for adults with multiple myeloma, bringing welcome hope for patients eligible for the treatment, according to researchers and physicians at Dana-Farber Cancer Institute.
Video
Next Questions: Chronic Lymphocytic Leukemia
Jennifer Brown, MD, PhD, shares about multiple treatments and drug therapies and how long patients can remain on them while determining the best outcomes.
News
Dana-Farber to Offer First CAR T-Cell Therapy for Indolent Follicular Lymphoma Following FDA Approval
The Food and Drug Administration (FDA) approval of the first CAR T-cell therapy for indolent follicular lymphoma, a slow growing, non-Hodgkin lymphoma (NHL), represents a key advance for patients with relapsed or refractory forms of the disease. Dana-Farber/Brigham and Women’s Cancer Center (DF/BWCC) will be a certified treatment center for the therapy.
News
Break Through Cancer Launches Collaborative Model Across Top U.S. Research Institutions in Pursuit of Cancer Cures
Break Through Cancer today announced its formal launch as a public foundation designed to find new solutions to the most intractable challenges in cancer.
News
CAR T-Cell Therapy Generates Lasting Remissions in Patients with Multiple Myeloma
In a major advance in the treatment of multiple myeloma, a CAR T-cell therapy has generated deep, sustained remissions in patients who had relapsed from several previous therapies, an international clinical trial has found.
News
Targeted Therapy for Children with Leukemia Can Provide Substantial Benefit, Study Finds
Testing tumor tissue for genetic alterations that can be targeted by drugs, a mainstay of treatment in a variety of cancers, can benefit many children with leukemia, investigators at Dana-Farber/Boston Children’s Cancer and Blood Disorders Center report in a new study. In some cases, such therapy can be lifesaving.